What does the microbiome mean for drug development? A growing number of pharmaceutical companies and biotechs are becoming interested in the trillions of microbes that live within our bodies – and how they impact our health. Microbiome research could lead to new approaches to targeting disease, either through live biotherapeutic products or traditional drug development approaches.
In this special supplement sponsored by Quay Pharma, experts from across the industry give their views on where the field of microbiome-based medicines is heading, and what the challenges will be moving forward. Featuring: Denise Kelly (Seventure), Ronnie Farquhar (Artugen Therapeutics), James Leigh (4D Pharma), Maireadh Pedersen and Ryan Wilson (Quay Pharma), James McIlroy (EnteroBiotix), Aoife Brennan (Synlogic), and Mike Romanos (Microbiotica).
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
